Peter Pytel to Biomarkers, Tumor
This is a "connection" page, showing publications Peter Pytel has written about Biomarkers, Tumor.
Integrating a Large Next-Generation Sequencing Panel into the Clinical Diagnosis of Gliomas Provides a Comprehensive Platform for Classification from FFPE Tissue or Smear Preparations. J Neuropathol Exp Neurol. 2019 03 01; 78(3):257-267.
High prevalence of MiTF staining in undifferentiated pleomorphic sarcoma: caution in the use of melanocytic markers in sarcoma. Histopathology. 2017 Apr; 70(5):734-745.
Primary Intracranial Myoepithelial Neoplasm: A Potential Mimic of Meningioma. Int J Surg Pathol. 2016 May; 24(3):243-7.
Expression of HIF-1 regulated proteins vascular endothelial growth factor, carbonic anhydrase IX and hypoxia inducible gene 2 in hemangioblastomas. Folia Neuropathol. 2014; 52(3):234-42.
Expression profiling of 519 kinase genes in matched malignant peripheral nerve sheath tumor/plexiform neurofibroma samples is discriminatory and identifies mitotic regulators BUB1B, PBK and NEK2 as overexpressed with transformation. Mod Pathol. 2013 Jul; 26(7):930-43.
SOX9 and SATB2 immunohistochemistry cannot reliably distinguish between osteosarcoma and chondrosarcoma on biopsy material. Hum Pathol. 2022 03; 121:56-64.
Interferon-gamma induced medulloblastoma in the developing cerebellum. J Neurosci. 2004 Nov 10; 24(45):10074-83.